Comparison between beta‐blockers and calcium channel blockers in patients with atrial fibrillation according to renal function
Clinical Cardiology · 2024
DOI: 10.1002/clc.24257 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von José Antonio Parada Barcia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, University Hospital Alvaro Cunqueiro, Vigo, Spain. Hauptthemen laut MEDLINE: Atrial Fibrillation, Calcium Channel Blockers, Adrenergic beta-Antagonists, Glomerular Filtration Rate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rate control is the most commonly employed first‐line management strategy for atrial fibrillation (AF) in patients with chronic kidney disease (CKD). Principal agents used to control heart rate (HR) include beta‐blockers (BB) and nondihydropyridine calcium channel blockers (ND‐CCB). However, there is a paucity of published studies of the differences between those drugs in CKD patients. Hypothesis The present study aimed to investigate the differences, in terms of hospitalizations due to a poor HR control, in patients with AF under a rate‐control strategy according to glomerular filtration rate (GFR).
Methods
The study cohort included 2804 AF patients under rate‐control regime (BB or ND‐CCB) between January 2014 and April 2020. The end point, determined by competing risk regression, was hospitalizations for AF with rapid ventricular response (RVR), slow ventricular response (SVR), and need for pacemaker.
Results
On multivariate analysis, there were no statistical differences between ND‐CCB and BB for subjects with GFR > 60 mL/min/1.73 m 2 (subdistribution heart rate [sHR] 0.850, 95% confidence interval [CI]: 0.61–1.19; p = .442) and GFR 30–59 mL/min/1.73 m 2 (sHR 1.242, 95% CI: 0.80–1.63; p = .333), while in patients with GFR < 30 mL/min/1.73 m 2 , ND‐CCB therapy was associated with increased hospitalizations due to poor HR control (sHR 4.53, 95% CI: 1.19–17.18; p = .026).
Conclusion
In patients with GFR ≥ 30 mL/min/1.73 m 2 , the choice of ND‐CCB or BB had no impact on hospitalizations due to poor HR control, while in GFR < 30 mL/min/1.73 m 2 , a possible association was detected. The effects of these drugs on GFR < 30 mL/min/1.73 m 2 would require further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, University Hospital Alvaro Cunqueiro, Vigo, Spain.
- University of Santiago de Compostela, Santiago, Spain.
- Health Research Institute Galicia Sur, Vigo, Spain.
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Zitieren
APA
Parada Barcia, J. A., Raposeiras Roubin, S., Fernández, D. G., García, A. G., Otero, C. I., González Bermúdez, I., Íñiguez Romo, A., & Abu-Assi, E. (2024). Comparison between beta‐blockers and calcium channel blockers in patients with atrial fibrillation according to renal function. Clinical Cardiology. https://doi.org/10.1002/clc.24257
Vancouver
Parada Barcia JA, Raposeiras Roubin S, Fernández DG, García AG, Otero CI, González Bermúdez I, et al. Comparison between beta‐blockers and calcium channel blockers in patients with atrial fibrillation according to renal function. Clinical Cardiology. 2024. doi:10.1002/clc.24257
BibTeX
@article{ParadaBarcia2024,
author = {Parada Barcia, José Antonio and Raposeiras Roubin, Sergio and Fernández, David González and García, André González and Otero, Carla Iglesias and González Bermúdez, Inmaculada and Íñiguez Romo, Andrés and Abu-Assi, Emad},
title = {Comparison between beta‐blockers and calcium channel blockers in patients with atrial fibrillation according to renal function},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24257}
}
EUVIMED